Clermont Oncology Center — research payments reported

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$259,896	14
2024	Research	$175,683	12
2023	Research	$227,064	5
2022	Research	$29,810	3

Breakdown

Who paid Research payments · program years 2022–2025

Merck Sharp & Dohme Corporation $608,542 19 payments
Hexal AG $83,306 7 payments
BioNTech SE $582 7 payments
E.R. Squibb & Sons, L.L.C. $23 1 payment

Studies the money was for Research payments · program years 2022–2025

A Phase 3 Randomized, Open-label Clinical Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase MK-3475A Versus Intravenous Pembrolizumab, Administered With Chemotherapy, in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer $235,729 6 payments
An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab MK-3475 in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater than or Equal to 50 Metastatic Non-small Cell Lung Cancer KEYNOTE D46,EVOKE-03. $180,562 6 payments
Cgme751a12101 $83,306 7 payments
An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX 106 and INBRX-106 in Combination with Pembrolizumab in Subjects with Locally Advanced or Metastatic Solid Tumors $57,960 1 payment
A Phase 3 Randomized, Open-label Clinical Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase MK-3475A Versus Intravenous Pembrolizumab, Administered With Chemotherapy, in the First-line Treatm $46,548 1 payment
KEYMAKER-U01 Substudy 01J# A Randomized Phase 2 Umbrella Study With Rolling Arms of Investigational Agents for First-line Treatment of Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer NSCLC With KRAS G12C Mutations $33,683 1 payment
KEYMAKER-U01 Substudy 01F# A Phase 1b,2 Umbrella Study With Rolling Arms of Investigational Agents for Previously Treated Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer NSCLC With KRAS G12C Mutations $27,658 1 payment
An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX 106 and INBRX-106 in Combination with Pembrolizumab in Subjects with Locally Advanced or Metastatic Solid Tumors $15,760 1 payment
KEYMAKER-U01 Substudy 01J# A Randomized Phase 2 Umbrella Study With Rolling Arms of Investigational Agents for First-line Treatment of Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer NSCLC With KRAS G12C Mutations $5,738 1 payment
A Phase 3 Randomized, Open-label Clinical Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase MK-3475A Versus Intravenous Pembrolizumab, Administered With Chemotherapy, in the First-line Treatm $4,905 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.